June 2, 2021Open Access

Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial

Key Points

Key points are not available for this paper at this time.

Abstract

Among patients with stage I HER2+ BC, one year of adjuvant T-DM1 was associated with excellent 3-year iDFS, but was not associated with fewer CRT compared with TH.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Cite this study

Tolaney et al. (Wed,) studied this question.

www.synapsesocial.com/papers/69daaff44a1e15904c835b11 — DOI: https://doi.org/10.1200/jco.20.03398

Authors

Sara M. Tolaney

Nabihah Tayob

Chau T. Dang

Journals

Journal of Clinical Oncology

Actions

Institutions

Harvard University

University of Washington

University of Michigan

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Cite this study

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion